Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
JBIOthis companyJade Biosciences, Inc.	$15.82	-3.8×	1.46×	0×	-3.11×	-80.4%	0.0%	0.0%	0.0%	-38.3%	-34.1%	-19.6%	0×	0.69×	0×	20.33×	15.6%	2	15.73	2	C+
ACRSAclaris Therapeutics, Inc.	$4.19	-5.68×	3.58×	47.18×	-5.45×	-122.2%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	2	-2.65	1	D+
CTNMContineum Therapeutics, Inc.	$10.08	-5.27×	1.21×	0×	-3.68×	-74.9%	0.0%	0.0%	0.0%	-23.0%	-25.3%	-17.5%	0.03×	0.99×	0×	27.5×	0.0%	2	16.76	2	C+
DWTXDogwood Therapeutics, Inc.	$1.23	-0.96×	0.46×	0×	-0.82×	-43.2%	0.0%	0.0%	0.0%	-45.7%	-32.1%	-45.7%	0×	0.19×	0×	2.76×	0.0%	1	-1.2	3	B
ELDNEledon Pharmaceuticals, Inc.	$2.80	-2.7×	1.52×	0×	-2.24×	-91.0%	0.0%	0.0%	0.0%	-56.3%	-55.1%	-50.4%	0.01×	0.49×	0×	7.4×	0.0%	1	-4.22	2	C
KYTXKyverna Therapeutics, Inc.	$5.11	-2.58×	1.79×	0×	-2.02×	-60.9%	0.0%	0.0%	0.0%	-69.4%	-65.0%	-36.9%	0.12×	0.6×	-347.29×	7.75×	0.0%	1	-0.9	2	C
Peer median	—	-2.7×	1.52×	0×	-2.24×	-74.9%	0.0%	0.0%	0.0%	-56.3%	-55.1%	-36.9%	0.02×	0.49×	0×	7.4×	0.0%	1	-1.2	2	—